NEUROONE MEDICAL TECHNOLOGIES Corp Files Form 4

TL;DR

NEUROONE MEDICAL TECHNOLOGIES Corp filed a Form 4 on 4/7/26 for 4/3/26 transactions.

AI Summary

On April 7, 2026, NEUROONE MEDICAL TECHNOLOGIES Corp filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transactions that occurred on April 3, 2026. The filing was accepted by the SEC on April 7, 2026.

Why It Matters

Form 4 filings indicate changes in stock ownership by company insiders, which can signal their confidence or lack thereof in the company's future performance.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of stock ownership changes by insiders and does not inherently indicate positive or negative company performance.

Key Numbers

• 4 — Form Type (Statement of changes in beneficial ownership of securities)

Key Players & Entities

• NEUROONE MEDICAL TECHNOLOGIES Corp (company) — Issuer
• 0001500198 (company) — Issuer CIK
• 0001215243-26-000004 (filing_id) — SEC Accession Number
• 2026-04-07 (date) — Filing Date
• 2026-04-03 (date) — Period of Report
• BUCKMAN PAUL (person) — Reporting Person
• 0001215243 (person) — Reporting Person CIK

FAQ

Filing Documents

• primary_doc.html (4)
• primary_doc.xml (4) — 6KB
• 0001215243-26-000004.txt ( ) — 7KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * BUCKMAN PAUL (Last) (First) (Middle) 7599 ANAGRAM DR. (Street) EDEN PRAIRIE MINNESOTA 55344 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 04/03/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 04/03/2026 A 41,929 (1) A $ 0 178,733 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Option to Purchase Common Stock $ 0.795 04/03/2026 A 26,036 (2) 04/02/2036 Common Stock 26,036 $ 0 26,036 D Explanation of Responses: 1. Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. 2. The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. /s/ Emily Johns, by Power of Attorney 04/07/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)